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Description of Case
A 46-year-old woman was hospitalized
due to fever of up to 39uC of one week’s
duration. The patient complained of
weakness, night sweats, and weight loss
for two weeks prior to admission. The
patient had no past medical history, and
did not take any medications, supple-
ments, or illicit drugs. She was born and
lived all her life in a rural village. She was
indirectly exposed to farm animals and
pets, yet had no close contact with these,
and her family was not engaged in
agricultural work. She denied having been
bitten by ticks or fleas. There was no
history of recent foreign travel or eating
raw meat or unpasteurized milk. She
reported no rashes, arthralgia, dryness of
eyes, mouth ulcers, or mucocutaneous
bleeding.
On examination she appeared pale and
sweaty. The cardiorespiratory examina-
tion was unremarkable. A markedly tender
and enlarged liver and spleen, 3 cm and
10 cm below the costal margins, respec-
tively, were noted, with no palpable lymph
nodes. Periorbital and peripheral extrem-
ity edema was also present.
What Are Likely Etiologies for
This Patient’s High Fever and
Organomegaly?
Physicians commonly see patients with
prolonged fever. There are many different
possible etiologies, most commonly infec-
tious, but neoplastic and inflammatory or
autoimmune disorders may also be a
possibility. Less common conditions in-
clude drug-related fevers, factitious (i.e.,
self-induced) fevers, and other rare diseas-
es. Some patients with prolonged fever will
remain undiagnosed despite an intensive
diagnostic work-up.
The diagnostic approach should be
based on any potential clues in the
patient’s history, physical examination,
and routine screening blood tests and
cultures. In this case the history gives no
apparent clue; therefore the organomegaly
should be the basis for the assessment. The
massive splenomegaly narrows down the
differential diagnosis, as only a few
conditions generally cause this degree of
splenic enlargement (Box 1). These include
infectious causes, such as bacterial (ty-
phoid fever, Mycobacterium tuberculosis,o r
AIDS with M. avium complex) and fungal
agents (histoplasmosis), but more com-
monly splenomegaly results from parasitic
diseases such as malaria and leishmaniasis.
Viruses such as those causing infectious
mononucleosis, i.e., Epstein-Barr virus
(EBV) and cytomegalovirus (CMV), or
hepatitis viruses rarely cause this degree of
organomegaly. Hematologic disorders
such as myeloproliferative diseases, lym-
phoma, or chronic lymphocytic leukemia
and hairy cell leukemia, as well as
thalassemia intermedia and autoimmune
hemolytic anemia, should also be consid-
ered. Infiltrative diseases such as Gaucher
disease, sarcoidosis, and amyloidosis may
potentially cause massive splenomegaly.
The previous history of complete health,
the tenderness of the spleen, and the
abrupt onset of high fever all argue for
an acute rather than a chronic smoldering
disease (such as an infiltrative, autoim-
mune, or a chronic hematologic neoplastic
disease). Nevertheless, a chronic disease
cannot be ruled out and should be
investigated as an underlying disorder
preceding a more common cause for
prolonged fever.
Multiple blood, urine, and stool cultures
were negative. The patient’s laboratory
results revealed pancytopenia with 2,800
leukocytes/mm
3 (2,200 neutrophils, 400
lymphocytes, 200 monocytes, and no
eosinophils or basophils/mm
3). The he-
moglobin level was 98 g/l, and the platelet
count was 59,000/mm
3. The reticulocyte
count was 1.5%. The erythrocyte sedi-
mentation rate was elevated at 104 mm/h.
Her prothrombin time and partial throm-
boplastin time were prolonged (41.5% and
46.6 seconds, respectively), and the fibrin-
ogen level was low at 82 mg/dl. The
peripheral blood smear showed mature
white blood cells with a mild left shift, and
a few red blood cell schistocytes. The
serum creatinine and urea levels and
electrolytes were all normal. Liver function
tests (LFTs) were elevated at three to four
times the normal values, with hyperbiliru-
binemia of 27 mmol/l (0–17 mmol/l).
The lactate dehydrogenase was markedly
elevated at 4,245 U/l (300–620 U/l). An-
ti-nuclear antibody, rheumatoid factor,
anti-neutrophilic cytoplasmatic antibody,
anti-cardiolipin and circulating anticoagu-
lants were all negative, as were direct
Coombs tests. Serology for Mycoplasma,
Brucella, Legionella, Q fever, spotted fever,
murine typhus, HIV, EBV, CMV, hepa-
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leishmaniasis (Leishmania infantum, L. dono-
vani, and L. chagasi) were all negative. Acid-
fast stains of sputum and blood cultures for
tuberculosis were negative. Thick blood
films for malaria and Borrelia were nega-
tive. A computed tomography scan of the
chest, abdomen, and pelvis showed a
homogeneously enlarged liver and spleen
(splenic long axis, 24 cm). The echocardi-
ography showed normal ventricular func-
tion, and no valvular abnormalities. The
patient continued to have daily spiking
fevers and sweats, and her cytopenias,
coagulation defects, and LFTs worsened.
In the Absence of a Laboratory
Diagnosis of This Patient’s
Signs and Symptoms, What
Should Be the Next Step?
The main laboratory feature observed is
the pancytopenia. However, most, if not all
of the differential diagnosis of prolonged
fever and splenomegaly may comprise that
of blood cytopenias to some extent. Hema-
tologic malignancies may involve the bone
marrow and therefore lead to cytopenia.
The lack of eosinophils, basophils, or
nucleated red cells and the morphologically
normal circulating white blood cells make a
myeloproliferative disease unlikely. The
lack of enlarged lymph nodes and the
absence of atypical cells in the peripheral
blood make another hematologic malig-
nancy less likely. Furthermore, the spleno-
megaly may itself cause hypersplenism and
peripheral blood cytopenias. The coagula-
tion abnormalities of both prothrombin
time and partial thromboplastin time, with
low fibrinogen (which is an acute phase
reactant expected to rise in any inflamma-
tory state) and circulating schistocytes,
implies the presence of disseminated intra-
vascular coagulation (DIC), and the mark-
edly elevated LFTs point to a more severe
disease. The unremarkable autoimmune
serologies are also against such an ongoing
process. Infections that cause immune
hyperplasia or organ infiltration may in-
volve the bone marrow, causing cytopenias
as well. Because all the above tests do not
reveal the etiology for this patient’s severe
disease, a tissue biopsy is needed. As the
liver and spleen appear radiologically
homogenous with no focal lesions for
biopsy, a bone marrow biopsy and aspira-
tion, including multiple cultures for the
different infectious diseases discussed,
should be the next step.
A bone marrow biopsy was performed,
revealing a hypercellular marrow with no
evidence of malignancy. The aspirate
showed the presence of many monocytes
and marked hemophagocytosis (Figure 1),
with no evidence of immature cells.
Cytogenetic examination showed no ab-
normalities, and the immunophenotyping
showed monocytosis with no excess blasts.
The trephine biopsy was stained for CD3,
CD20, CD30, CD68, and leukocyte
common antigen with no evidence of
lymphoma. T cell receptor gene rear-
rangement was negative. PCR examina-
tions of the bone marrow for EBV, CMV,
human herpesvirus-6, and Leishmania were
found to be negative and no apparent
causative agent or disease found. Cultured
marrow for bacteria and fungi was nega-
tive. A repeat bone marrow examination
resulted in similar findings to the first one
that was performed.
As the patient’s symptoms continued to
progress, a transjugular liver biopsy was
performed, revealing hemophagocytosis
with no pathogen or malignancy. Addi-
tional blood tests showed a ferritin level of
15,614 ng/ml, triglycerides of 4.35 mmol/
l (0–2.3), and a soluble interleukin 2
receptor level of 9,577 U/ml (,1,000).
The patient was deemed too ill to
undergo splenectomy, and she was diag-
nosed as having a hemophagocytic syn-
drome. Empiric treatment with high-dose
immunoglobulin (2 gm per kg) and
300 mg of hydrocortisone daily did not
evoke a clinical response. High-dose
dexamethasone (20 mg daily) was initiat-
ed, followed by cyclosporin A with a rapid
and substantial improvement during the
next few days. Her fever subsided, blood
counts rose, and DIC resolved. She felt
well and was discharged in an excellent
condition with normal blood tests. She
continued treatment, tapering the steroid
dose to completion, and was maintained
on cyclosporin A at a dose of 5 mg/kg a
day. At a monthly follow-up the patient
was free of symptoms, and continued to
have normal blood counts for a period of
three months. An abdominal ultrasound
showed the reduction of both liver and
spleen to almost normal (15 cm). Bone
marrow aspiration and biopsy were per-
Box 1: Diseases Associated with Massive Splenomegaly
Massive splenomegaly is defined as a spleen extended greater than 8 cm below
left costal margin and/or weighing more than 1,000 g.
N Hematologic
# Myeloid
& Chronic myelogenous leukemia
& Myelofibrosis with myeloid metaplasia
& Polycythemia vera
# Lymphoid
& Chronic lymphocytic leukemia
& Hairy cell leukemia
& Lymphoma
# Benign
& Thalassemia major or intermedia
N Infectious
# Parasitic
& Visceral leishmaniasis
& Hyper-reactive malarial syndrome
& Schistosomiasis
# Bacterial
& Mycobacterial/AIDS with Mycobacterium avium complex
& Typhoid fever
# Viral
& EBV, CMV (rarely gives massive splenomegaly)
# Fungal
& Histoplasmosis
N Infiltrative
# Gaucher disease
# Sarcoidosis
# Diffuse splenic hemangiomatosis
N Autoimmune
# Autoimmune hemolytic anemia
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found to be morphologically normal.
Repeat PCR for EBV, which is strongly
associated with hemophagocytic lympho-
histiocytosis, was also negative. No other
PCR or serologies were sent at that time.
How Is Hemophagocytic
Syndrome Diagnosed and
Treated? Is This a Real Case of
Primary Hemophagocytic
Syndrome?
Hemophagocytic syndrome is a clinico-
pathologic entity. Its diagnosis is defined
by a set of presenting major signs and
symptoms (Box 2). The disease may be
familial or primary, and is observed mostly
in children, though it may be secondary to
malignancy (mostly T cell lymphomas),
infections (most often EBV related), auto-
immune diseases, or drugs. In this case the
criteria are completely fulfilled, but con-
sidering her age and the absence of a
relevant family history, the main question
that should be asked repeatedly is: what is
the primary process due to which this
hemophagocytosis results? Primary hemo-
phagocytosis is so rare at this age as to be
practically nonexistent. A continued
search for a malignancy or an infectious
organism should be performed, and sple-
nectomy should be considered.
The treatment for primary hemopha-
gocytic syndrome in children consists of
high-dose dexamethasone, cyclosporin A,
and etoposide-based chemotherapy. In
this patient, the use of this treatment
modality seemed appropriate considering
her severe clinical deterioration with no
underlying etiology found. It is still a
mystery that the primary cause of this
patient’s disease has not been found. The
patient’s response to immunosuppressive
therapy is not unusual. It should be kept in
mind that T cell lymphomas tend to
present with hemophagocytosis, even with
minimal disease, and that this type of
neoplasm may respond to lympholytic
steroids and cyclosporine A, which are T
cell depressants.
By the end of a three-month period
during which immunosuppression was
continued but doses gradually reduced
(Figure 2), the initial symptoms of fever
and weakness recurred. She was urgently
admitted with rapidly progressing pancy-
topenia, DIC, and elevated LFTs. Another
bone marrow aspiration, the sixth in
number, revealed for the first time mac-
rophages filled with organisms whose
appearance was consistent with that of
Leishmania amastigotes (Figure 3). Within
days, serology and a culture of the bone
marrow confirmed the diagnosis of Leish-
mania. In addition, PCR confirmed iden-
tification of L. infantum species. This form
of leishmaniasis is seen mostly in children
or immunosuppressed individuals in en-
demic areas of the world. It is the causative
agent of both the cutaneous and visceral
forms of leishmaniasis; the dog is its main
reservoir.
Treatment with liposomal amphotericin
B was initiated. The patient’s symptoms
disappeared within a few days, and her
laboratory abnormalities subsided. She
was discharged, and has continued to be
free of symptoms at routine follow-up for
two additional years. All past pathologic
preparations were thoroughly reviewed,
including bone marrow examinations and
liver biopsy, none revealing the Leishmania
parasites prior to the final diagnostic
examination. The patient gave her consent
for the publication of this case report.
Discussion
The term hemophagocytosis describes
the pathologic finding of activated macro-
phages and engulfing erythrocytes, leuko-
cytes, platelets, and their precursor cells
[1,2] as shown in this patient. It may also
Figure 1. Bone marrow aspirate showing monocytes (red arrows) engulfing red blood
cell precursors (black arrows). (Giemsa stain.)
doi:10.1371/journal.pmed.1000053.g001
Box 2: Criteria for the Diagnosis of HLH
Five out of eight should be present.
Major Clinical Criteria (all five should be evaluated):
N Fever
N Splenomegaly
N Cytopenia involving two or more cell lines
N Hypertriglyceridemia or hypofibrinogenemia
N Hemophagocytosis ( with no evidence for malignancy )
New Criteria
N Low or absent natural killer cell activity.
N A high serum ferritin level (.500 mg/l)
N A high soluble CD25 [soluble interleukin 2 receptor] (.2,400 U/ml)
(Adapted from the Histiocyte Society guidelines [2,17].)
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lymphohistiocytosis (HLH). The most
typical presenting signs and symptoms
are fever, hepatosplenomegaly, and cyto-
penias. Less frequently observed clinical
findings are neurological symptoms,
lymphadenopathy, edema, skin rash, and
jaundice [1,3,4]. Common laboratory
findings include hypertriglyceridemia, a
coagulopathy with hypofibrinogemia, and
elevated LFTs.
The entity comprises two different
conditions that may be difficult to distin-
guish from each other [2,5,6]: primary
and secondary HLH. Primary HLH,
found most often in young children, is a
hereditary transmitted disorder, consid-
ered to be an autosomal recessive disease,
affecting immune regulation. Recently,
mutations in one of two genes have been
found to underlie 40%–50% of cases: the
gene encoding perforin, the major im-
mune cytotoxic protein, and the gene
encoding MUNC 13-4, a protein involved
in exocytosis of perforin-bearing cytotoxic
granules during apoptosis [7]. Secondary
HLH, which is found in both children and
adults, comprises a lymphohistiocytic pro-
liferation with hemophagocytosis. It also
develops as a consequence of strong
immunological activation.
This secondary form is encountered
most often with severe infection. The
viral-associated [8], most often EBV-
related form is also termed fatal or
fulminant infectious mononucleosis, yet
other viruses have been implicated. At-
tempts should be made to screen for an
infection with EBV, CMV, and parvovirus
B19, either through serologic testing or
PCR, in-situ hybridization, or (in the case
of CMV) immunofluorescent antigen test-
ing. Serologic testing for HIV and human
herpesvirus-6 infection should also be
considered [9]. Bacterial infections such
as brucellosis, salmonellosis, tuberculosis,
and rickettsiosis have been reported to
cause this rare syndrome. Parasitic diseas-
es such as malaria and leishmaniasis may
also induce secondary HLH [7]. The
presentation of visceral leishmaniasis with
hemophagocytic syndrome is rare in all
age groups, especially in adults [10,11,12].
Furthermore, the Leishmania serological
test and bone marrow examination in-
cluded in the work-up may be initially
negative, necessitating repeated bone mar-
row procedures for diagnosis [10]. Indeed,
diagnosing Leishmania in this patient on the
sixth bone marrow aspirate (after five
previous negative examinations) is an
extreme example. HLH may also develop
subsequent to other forms of immunolog-
ical stress and activation, as in the
macrophage activating disorder in rheu-
matic diseases, but is most often seen
accompanying malignancy [13]. It has
been described during the course of active
lymphoma, but also in patients in com-
plete remission [14]. Even if an infection
known to be associated with HLH has
Figure 3. Bone marrow aspirate showing multiple parasites (black arrows) within and
released from the monocyte, consistent with the presence of Leishmania amastigotes.
(Giemsa stain.)
doi:10.1371/journal.pmed.1000053.g003
Figure 2. The patient’s diagnosis and treatment over the course of time (x-axis in days). y-axis denotes lactate dehydrogenase (LDH)
levels in blue, white blood cell counts (WBC) in red. Black arrows designate hospitalization onset. Green arrows designate bone marrow biopsy (BM)
or aspiration, red for liver biopsy (LB).
doi:10.1371/journal.pmed.1000053.g002
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cell receptor gene rearrangement tests
should be performed on bone marrow or
other tissue specimens to determine
whether an underlying T cell lymphoma
is present [9]. To further complicate the
diagnosis, T cell receptor rearrangements
can also be found in both EBV-associated
HLH and EBV-positive T cell lymphomas
[15], but have not yet been demonstrated
in other secondary forms of HLH.
HLH is considered to be the final
common pathway of different infectious
organisms as well as autoimmune diseases
and lymphomas, stemming from the same
process that causes immune activation.
The pathophysiology behind this excessive
activation, although apparent mainly in
the monocytic lineage, involves the inter-
actions of T cells and macrophages. The
major pathogenic role of TH1 hyperacti-
vation is suggested by high levels of
cytokines, such as interferon-c, tumor
necrosis factor-a, and interleukins 1 and
6, all of which are secreted by activated
TH1 cells [10]. These cytokines cause
enhanced phagocytosis in vitro. The major
role of TH1 is further suggested by the
coexistence of HLH TH1-related infec-
tions such as tuberculosis and leishmania-
sis, and by the therapeutic use of the T cell
depressant compound cyclosporin. All
support the hypothetical role of T cells as
a key element in the pathophysiology of
HLH. There are reports [10] describing
patients with secondary HLH due to
leishmaniasis who were treated with im-
munosuppressive agents, resulting in a
temporary long-term remission, highlight-
ing once again the immunologic reactivity
as the basis of HLH etiology rather than
the causative infectious agent. Yet, not all
patients with secondary HLH-related dis-
eases develop actual HLH symptoms.
Thus, the underlying immune modulation
deficiency that differentiates a patient
prone to developing HLH from his or
her counterpart who does not develop this
syndrome has yet to be determined.
It is well known that immunocompe-
tent, immunocompromised, immunosup-
pressed, and HIV patients are more prone
to acquiring or reactivating Leishmania
parasites easily, mainly in endemic areas
as seen in the Mediterranean area [16,17].
It could therefore be argued that, being
immune suppressed, the patient acquired
an opportunistic infection or activated a
dormant one [18].
This argument cannot be completely
disproved because the facts are equivocal.
The preliminary negative serology sup-
ports the possibility that the seroconver-
sion appearing later in the course of the
disease was a new opportunistic infection
caused by immunosuppressive treatment.
According to this hypothesis, the patient
had idiopathic HLH that resolved after
treatment with steroids and cyclosporine
A. While being immunosuppressed, she
acquired Leishmania, a second opportunis-
tic disease. Similarly, it could be argued
that the patient was asymptomatically
infected in the past and thus Leishmania
antibodies were undetectable [18,19].
Although this seems to be a reasonable
alternative explanation, there are a few
reasons to favor the hypothesis of Leish-
mania as the initial event causing the entire
syndrome. First, an initially negative assay
for Leishmania does not support the pres-
ence of a dormant infection but rather an
acute one with false negative results.
Previous reports of HLH and leishmania-
sis have described patients receiving im-
munosuppressive agents for their HLH
until their final diagnosis months later
[10]. Second, the possibility that the
patient had two concurrent very rare
diseases—idiopathic HLH and opportu-
nistic leishmaniasis—is unlikely. Third, the
fact that the ultimately diagnosed Leish-
mania infection manifested with precisely
the same signs and symptoms as the
primary HLH, as well as the fact that
there was rapid resolution of the entire
syndrome under the appropriate therapy
(liposomal amphotericin B) and cure (at
the present time the patient has been in
remission for more than two years), also
favors this theory.
In order to define a disease as primary
or idiopathic, one has to rule out all overt
or rare causes. It is important to repeat
blood tests and to repeat biopsies of the
suspected organs involved. Repeating the
bone marrow aspiration, a usually safe
procedure [20], seems to be the most
effective method of follow-up. When
hemophagocytosis is found, it may take
sequential repeated aspirations in order to
reveal its secondary etiology [10,21,22].
All adult patients may not have a clear
diagnosis of HLH. In a large case series, in
20 of 34 patients with HLH, no underlying
etiology was identified [23]. There is no
specific feature of HLH, but the disease is
often fatal, so that a prompt diagnosis is
mandatory. Diagnostic guidelines were
developed by the HLH Study Group in
1991 [6], including clinical, laboratory,
and histopathological findings (Box 1).
The disease may be underdiagnosed since
treating physicians do not often consider it
in the differential diagnosis of candidate
patients [2,6]. Some patients may express
one or more of the diagnostic criteria late
in the course of the disease. Thus, in the
absence of any specific marker of disease
in pediatric patients, treatment may be
started on the basis of a strong clinical
suspicion of primary HLH, before over-
whelming disease activity causes irrevers-
ible damage and the chances of response
to treatment are less likely [2,9,21].
Whether this rule can be applied to adult
patients, in whom the HLH is almost
always secondary, should be considered
individually.
Treatment of HLH is therefore depen-
dent on its cause. Infectious, neoplastic, or
autoimmune causes should be treated
promptly along with administering sup-
portive care. There are no randomized
trials for primary HLH due to the rarity of
this disease. Treatment is based on the
combination of immune suppression (such
as cyclosporin A) and chemotherapy (such
as etoposide) [22,23]. Intravenous immu-
noglobulins may also be beneficial. The
combination treatment plan (such as the
HLH-2004 protocol) is described in the
Histiocyte Society Web site protocol page
[23].
Key Learning Points
N Hemophagocytic syndrome is a severe disease with multiple causes, mostly
secondary to infectious organisms, but also to T cell lymphomas and
autoimmune diseases. It can also be (rarely and mostly in children) a primary
idiopathic disease or of familial origin.
N The cause of HLH should be repeatedly sought. If the diagnosis is not readily
found, repeated tissue sampling, serologies, and cultures should be obtained.
N Treatment of HLH should not be delayed as the disease progresses rapidly and
may be irreversible.
N Visceral leishmaniasis is a disease that may involve multiple organs. Diagnosis in
endemic areas should be sought vigorously, particularly in immunocompro-
mised hosts.
N Immunosuppressive therapy such as high-dose steroid treatment is a double-
edged sword. Although it may alleviate symptoms, it can mask the diagnosis.
PLoS Medicine | www.plosmedicine.org 5 April 2009 | Volume 6 | Issue 4 | e1000053Conclusions
Hemophagocytosis, being rare in itself,
is a diagnosis that is usually performed in
seriously ill, hospitalized patients. Leish-
maniasis, endemic in certain areas, yet
rare in most of the industrialized world,
may therefore be too rare for the treating
in-hospital clinician. The diagnosis thus
may be delayed in this setting. In the
patient described above, the tentative
diagnosis of primary or familial HLH
together with the presumed clinical im-
provement under immunosuppressive
therapy may have initially saved her life.
Nevertheless, this treatment had a major
contribution in the delay of ultimately
achieving the correct diagnosis. Perhaps a
splenectomy or splenic biopsy (both of
which have considerable risks in pancyto-
penic patients) could have revealed the
correct diagnosis earlier.
There are several lessons to be learned
(see Key Learning Points). HLH is a severe
disease that has to be identified and
treated promptly. The diagnosis can be
laborious and elusive, but the search for a
primary source should be continuously
sought, in particular for obscure patho-
gens. Treatment should be started without
delay, yet it should be kept in mind that
the use of immunosuppression may further
delay the diagnosis and definitive treat-
ment.
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